RareCyte® announced today the completion of a $24M financing from new and existing investors. The funding will drive the commercialization and applications for the Company’s new Orion spatial biology platform
RareCyte® announces a new rare cell detection kit, The Cell Discovery Kit, which enables custom panel development in your lab for the detection of circulating tumor cells (CTCs) that do not express epithelial markers
The September 15th webinar recording is now available.
Eric Kaldjian, MD, our Chief Medical Officer presents “Resolving the Complexity of Tissue Immune Response with Orion High-Dimensional Imaging”. This talk will describe the application of 17-plex immuno-oncology fluorescence panel and H & E images on the same tissue sections, all in a single scan, single stain process.
“The RareCyte CTC system has been analytically validated in our CAP/CLIA Laboratory and the validation and acceptance criteria met the needs of the clinical drug study team. In partnership with a global CRO, the CTC workflow is being successfully implemented.”
– Jeff Fill, Senior Director, Diagnostic and Experimental Pathology, Eli Lilly and Company